Drug Information Rounds

Wahlgren CF . Pathophysiology of itching in urticaria and atopic dermatitis. Allergy 1992; 47: 65–75.

Gupta MA Gupta AK Ellis CN . Antidepressant drugs in dermatology. Arch Dermatol 1987; 113: 647–52.

Phanuphak P Schocket AI Kohler PF . Treatment of chronic idiopathic urticaria with combined H₁ and H₂ receptor antagonists. Clin Allergy 1978; 8: 429–33.

Monroe EW Cohen SH Kalbfleisch J Schulz CI . Combined H₁ and H₂ antihistamine therapy in chronic urticaria. Arch Dermatol 1981; 117: 404–7.

Richelson E . Tricyclic antidepressants and histamine H₁-receptors. Mayo Clin Proc 1979; 54: 669–74.

Richelson E . Antimuscarinic and other receptor-blocking properties of antidepressants. Mayo Clin Proc 1983; 58: 40–6.

Greene SL Reed CE Schroeter AL . Double-blind crossover study comparing doxepin with diphenhydramine for the treatment of chronic urticaria. J Am Acad Dermatol 1985; 12: 669–75.

Hamelin BA Gravel A Turgeon J . Classic antihistamines inhibit CYP2D6 in vitro (abstract). Clin Pharmacol Ther 1996; 59: 172.

Goldsobel AB Rohr AS Siegel SC Spector SL Katz RM Rachelefsky GS . Efficacy of doxepin in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1986; 78: 867–73.

Neittaanmaki H Myohanen T Fraki JE . Comparison of cinnarizine, cyproheptadine, doxepin, and hydroxyzine in treatment of idiopathic cold urticaria: Usefulness of doxepin. J Am Acad Dermatol 1984; 11: 483–9.

Bernstein JE Whitney DH Soltani K . Inhibition of histamine-induced pruritus by topical tricyclic antidepressants. J Am Acad Dermatol 1981; 5: 582–5.

Drake LA Fallon JD Sober A . Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. J Am Acad Dermatol 1994; 31: 613–6.

Drake LA Millikan LE . The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Arch Dermatol 1995; 131: 1403–8.

Doxepin cream for pruritus. Med Lett 1994; 36: 99–100.

Ormerod AD . Urticaria: Recognition, causes, and treatment. Drugs 1994; 48: 717–29.

Hansen-Flaschen JH Brazinsky S Basile C Lanken PN . Use of sedating drugs and neuromuscular blocking agents in patients requiring mechanical ventilation for respiratory failure, a national survey. JAMA 1991; 266: 2870–5.

Meyer KC Prielipp RC Grossman JE Coursin DB . Prolonged weakness after atracurium in two intensive care unit patients. Anesth Analg 1994; 78: 772–4.

Vandenbrom RHG Wierda JMKH . Pancuronium bromide in the intensive care unit: A case of overdose. Anesthesiology 1988; 69: 996–7.

Hogue CW Martyn J Baker TR Vouros P . Recovery of pancuronium from peritoneal dialysate in a severely burned child. Anesth Analg 1991; 73: 83–6.

Watling SM Dasta JF . Prolonged paralysis in intensive care unit patients after the use of neuromuscular blocking agents: A review of the literature. Crit Care Med 1994; 22: 884–93.

Cozanitis D Haapanen E . Studies on muscle relaxants during hemodialysis. Acta Anaesth Scand 1979; 23: 225–34.

Aweeka FT . Dosing of drugs in renal failure. In: Young LY Koda-Kimble MA , eds. Applied therapeutics: The clinical use of drugs. 6th ed. Vancouver, WA: Applied Therapeutics Inc., 1995: 32–3–32–4.

Aronoff GR Erbeck KM . Prescribing drugs for dialysis patients. In: Henrich WL , eds. Principles and practice of dialysis. Baltimore: Williams and Wilkins, 1994: 89–97.

Package insert. Tracrium (atracurium besylate). Research Triangle Park, NC: Burroughs Wellcome Co., September 1992.

Package insert. Nimbex (cisatracurium besylate). Research Triangle Park, NC: Glaxo Wellcome, December 1995.

Foldes FF Deery A . Protein binding of atracurium and other short-acting neuromuscular blocking agents and their interaction with human cholinesterases. Br J Anaesth 1983; 55 (suppl):31S–4S.

Ward S Weatherley BC . Pharmacokinetics of atracurium and its metabolites. Br J Anaesth 1986; 58 (suppl):6S–10S.

De Bros FM Lai A Scott R deBros J Batson AG Goudsouzian N . Pharmacokinetics and pharmacodynamics of atracurium during isoflurane anesthesia in normal and anephric patients. Anesth Analg 1986; 65: 743–6.

Ward S Boheimer N Weatherley BC Simmonds RJ Dopson TA . Pharmacokinetics of atracurium and its metabolites in patients with normal renal function, and in patients in renal failure. Br J Anaesth 1987; 59: 697–706.

Vandenbrom RHG Wierda JMKH Agoston S . Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. Clin Pharmacokinet 1990; 19: 230–40.

Parker CJR Jones JE Hunter JM . Disposition of infusions of atracurium and its metabolite, laudanosine, in patients in renal and respiratory failure in an ITU. Br J Anaesth 1988; 61: 531–40.

Shearer ES O'Sullivan EF Hunter JM . Clearance of atracurium and laudanosine in the urine and by continuous venovenous haemofiltration. Br J Anaesth 1991; 67: 569–73.

Package insert. Pancuronium bromide. Irvine, CA: Gensia Laboratories, March 1992.

Dulvaldestin P Henzel D . Binding of tubocurarine, fazadinium, pancuronium and ORG NC 45 to serum proteins in normal man and in patients with cirrhosis. Br J Anaesth 1982; 54: 513–6.

Wood M Stone WJ Wood AJJ . Plasma binding of pancuronium: Effects of age, sex, and disease. Anesth Analg 1983; 62: 29–32.

Cronnely R Fisher DM Miller RD Gencarelli P Nguyen-Gruenke L Castagnoli N . Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) and pancuronium in anaesthesized humans. Anesthesiology 1983; 58: 405–8.

McLeod K Watson MJ Rawlins MD . Pharmacokinetics of pancuronium in patients with normal and impaired renal function. Br J Anaesth 1976; 48: 341.

Package insert. Norcuron (vecuronium bromide). West Orange, NJ: Organon Inc., July 1993.

Fahey MR Morris RB Miller RD Nguyen TL Upton RA . Pharmacokinetics of ORG NC 45 (Norcuron) in patients with and without renal failure. Br J Anaesth 1981; 53: 1049–53.

Segredo V Caldwell JE Matthay MA Sharma ML Gruenke LD Miller RD . Persistent paralysis in critically ill patients after long-term administration of vecuronium. N Engl J Med 1992; 327: 524–8.

Package insert. Nuromax (doxacurium chloride). Research Triangle Park, NC: Burroughs Wellcome Co., March 1991.

Package insert. Zemuron (rocuronium bromide). West Orange, NJ: Organon Inc., February 1994.

van den Broek L Wierda JMKH Smeulers NJ van Santen GJ Leclercq MGL Hennis PJ . Clinical pharmacology of rocuronium (ORG 9426): Study of the time course of action, dose requirement, reversibility, and pharmacokinetics. J Clin Anesth 1994; 6: 288–96.

Alvarez-Gomez JA Estelles ME Fabregat J Perez F Brugger AJ . Pharmacokinetics and pharmacodynamics of rocuronium bromide in adult patients. Eur J Anaesthesiol 1994; 11 (suppl 9):53–6.

Wierda JMKH Kleef UW Lambalk LM Kloppenburg WD Agoston S . The pharmacodynamics and pharmacokinetics of ORG9426, a new nondepolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. Can J Anaesth 1991; 38: 430–5.

Szenohradszky J Fisher DM Segredo V Caldwell JE Bragg P Sharma ML . Pharmacokinetics of rocuronium bromide (ORG 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. Anesthesiology 1992; 77: 899–904.

Larijani GE Gratz I Silverberg M Jacobi AG . Clinical pharmacology of the neuromuscular blocking agents. DICP Ann Pharmacother 1991; 25: 54–64.

Agoston S Vandenbrom RHG Wierda JMKH . Clinical pharmacokinetics of neuromuscular blocking drugs. Clin Pharmacokinet 1992; 22: 94–115.

Fahey MR Rupp SM Canfell C Fisher DM Miller RD Sharma M . Effect of renal failure on laudanosine excretion in man. Br J Anaesth 1985; 57: 1049–51.

Chapple DJ Miller AA Ward JB Wheatley PL . Cardiovascular and neurological effects of laudansine. Br J Anaesth 1987; 59: 218–25.

Miller RDM Agoston S Booij LHDJ Kersten UW Crul JF Ham J . The comparative potency and pharmacokinetics of pancuronium and its metabolites in anaesthetized man. J Pharmacol Exp Ther 1978; 207: 539–43.

Shapiro BA Warren J Egol AB Greenbaum DM Jacobi J Nasraway SA . Practice parameters for sustained neuromuscular blockade in the adult critically ill patient: An executive summary. Crit Care Med 1995; 23: 1601–5.

Tschida SJ Hoey LL Mather D Vance-Bryan K . Train-of-four: To use or not to use. Pharmacotherapy 1995; 15: 546–50.

Rudis MI Guslits BG Zarowitz BJ . Technical and interpretive problems of peripheral nerve stimulation in monitoring neuromuscular blockade in the intensive care unit. Ann Pharmacother 1996; 30: 165–72.

Coursin DB Prielipp RC . Prolonged paralysis with atracurium infusion. Crit Care Med 1995; 23: 1155–6.

Gooch JL . Prolonged paralysis after neuromuscular blockade. Clin Toxicol 1995; 33: 419–26.

Kassel NF Drake CG . Review of the management of saccular aneurysms. Neurol Clin North Am 1983; 1: 73–86.

Hassan D Wijdicks EFM Vermeulen M . Hyponatremia is associated with cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage. Ann Neurol 1990; 27: 106–8.

Cort JH . Cerebral salt wasting syndrome. Lancet 1954; 1: 752–4.

Peters JP Welt LG Sims EAH Orlof J Needham J . A salt wasting syndrome associated with cerebral disease. Trans Assoc Am Physicians 1950; 63: 57–64.

Doczi T Bende J Huszka E Kiss J . Syndrome of inappropriate secretion of antidiuretic hormone after subarachnoid hemorrhage. Neurosurgery 1981; 9: 394–7.

Wijdicks EFM Vermeulen M Van Brummelen P van Gijn J . The effect of fludrocortisone acetate on plasma volume and natriuresis in patients with aneurysmal subarachnoid hemorrhage. Clin Neurol Neurosurg 1988; 90: 209–14.

Nelson PB Seif SM Maroon JC Robinson AG . Hyponatremia in intracranial disease: Perhaps not the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Neurosurg 1981; 55: 938–41.

Ishikawa SE Saito T Kaneko K Okada K Kuzuya T . Hyponatremia responsive to fludrocortisone acetate in elderly patients. Ann Intern Med 1987; 106: 187–91.

Ganong CA Kappy MS . Cerebral salt wasting in children: The need for recognition and treatment. Am J Dis Child 1993; 147: 167–9.

Isotani E Suzuki R Tomita K Mituhiko H Monma S Marumo F . Alterations in plasma concentrations of natriuretic peptides and antidiuretic hormone after subarachnoid hemorrhage. Stroke 1994; 25: 2198–203.

Moses AM Streeten DHP . Disorders of neurohypophysics. In: Martin JB Fauci AS Kasper DL Isselbacher KJ Braunwald E Wilson JD , eds. Harrison's principles of internal medicine. New York: McGraw-Hill, Inc., 1994: 1921–30.

Wijdicks EFM Vermeulen M Hijdra A van Gijn J . Hyponatremia and cerebral infarction in patients with ruptured intracranial aneurysms. Is fluid restriction harmful? Ann Neurol 1985; 17: 137–40.

Goldfien A Laidlaw JC Haydar Abu N Renold AE Thorn GW . Fluorohydrocortisone and chlorohydrocortisone, high potent derivatives of compound F. N Engl J Med 1955; 252: 415–21.

Thorn GW Renold AE Morse WI Goldfien A Reddy WJ . Highly potent adrenal cortical steroids: Structure and biologic activity. Ann Intern Med 1955; 43: 979–1000.

Ehrlich EN Lindheimer MD . Effect of mineralocorticoid and adrenocorticotropic hormone administration on electrolyte and aldosterone excretion in normal gravid women: Absence of kaliresis despite corticoid-induced sodium retention. J Lab Clin Med 1970; 76: 1034–35.

Hasan D Lindsay KW Wijdicks EFM Murray GD Brouwers PJAM Bakker WH . Effect of fludrocortisone acetate in patients with subarachnoid hemorrhage. Stroke 1989; 20: 1156–61.

Wijdicks EFM Vermeulen M ten Haaf JA Hijdra A Bakker WH van Gijn J . Volume depletion and natriuresis in patients with ruptured intracranial aneurysm. Ann Neurol 1985; 18: 211–6.

Kassel N Peerless S Durward JQ Beck DW Drake CG Adams HP . Treatment of ischemic deficits from vasospasm with intravascular volume expansion and induced arterial hypertension. Neurosurgery 1979; 4: 223–6.

Pritz MB Gianotta SL Kindt GW McGillicuddy JE Prager RL . Treatment of patients with neurological deficits, associated with cerebral vasospasm by intravascular volume expansion. Neurosurgery 1978; 3: 364–8.

Ebelin P Koivisto V . Physiologic importance of dehydroepiandrosterone. Lancet 1994; 343: 1479–81.

Migeon CJ Plager J . Identification and isolation of dehydroepiandrosterone from peripheral human plasma. J Biol Chem 1954; 209: 767–72.

Orentreich N Brind J Rizer R Vogelman J . Age changes and differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 1984; 59: 551–5.

Barrett-Connor E Khaw KT Yen SS . A prospective study of dehydroepiandrosterone sulfate, mortalilty and cardiovascular disease. N Engl J Med 1986; 315: 1519–24.

Buffington AK Pourmotabbed G Kitabchi AE . Case report: Amelioration of insulin resistance in diabetes with dehydroepiandrosterone. Am J Med Sci 1993; 306: 320–4.

Morales AJ Nolan JJ Nelson JC Yen SS . Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994; 78: 1360–7.

Merrill CR Harrison MG Sunderland T . Plasma dehydroepiandrosterone levels in HIV infection (letter). JAMA 1989; 261: 1149.

Membrano L Irony I Dere W Klein R Biglieri E Cobb E . Adrenocortical function in the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1987; 65: 482–7.

Loria RM Inge TH Cook SS Szakal AK Regelson W . Protection against lethal viral infections with the native steroid dehydroepiandrosterone (DHEA). J Med Virol 1988; 26: 301–14.

Cupps TR Fauci AS . Corticosteroid mediated immunoregulation in man. Immunol Rev 1982; 65: 133–55.

Wichmann U Wichmann G Krause W . Serum levels of testosterone precursors, testosterone and estradiol in animal species. Exp Clin Endocrinol 1984; 83: 283–90.

Daynes RA Dudley DJ Araneo BA . Regulation of murine lymphokine production in vivo. Eur J Immunol 1990; 20: 793–802.

Kovacs JA Baseler M Dewer R Vogel S Davey RT Falloon J . Increases in the CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N Engl J Med 1995; 332: 567–75.

Villette JM Bourin P Doinel C Mansour I Fiet J Boudou P . Circadian variations in plasma levels of hypophyseal, adrenocortical and testicular hormones in men infected with human immunodeficiency virus. J Clin Endocrinol Metab 1990; 70: 572–7.

Jacobson MA Fusaro RE Galmarini M Lang W . Decreased serum dehydroepiandrosterone is associated with an increased progression of human immunodeficiency virus infection in men with CD4(+) cell counts of 200–499. J Infect Dis 1991; 164: 864–8.

Goedart JJ Kessler CM Aledort LM . A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med 1989; 321: 1141–8.

Mulder JW Frissen J Krijen X Endert E de Wolf F Goudsmit J . Dehydroepiandrosterone as predictor for progression to AIDS in asymptomatic human immunodeficiency virus-infected men. J Infect Dis 1992; 165: 413–8.

O'Brien WA Hartigan PM Martin D . Changes in plasma HIV-1 RNA and CD4(+) lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996; 334: 426–31.

Dyner TS Lang W Geaga J Golub A Stites D Winger E . An open-label dose escalation trial of oral dehydroepiandrosterone tolerance and pharmacokinetics in patients with HIV disease. J Acquir Immune Defic Synd 1993; 6: 459–65.

Hasheeve D Salvato P Thompson C . DHEA: a potential treatment for HIV disease (abstract). International Conference on AIDS: Institute, TX, Aug 7–12, 1994;10(1):223.

Chatteron RT Green D Harris S Grossman A Hechter O . Longitudinal study of adrenal steroids in a cohort of HIV-infected patients with hemophilia. J Lab Clin Med 1996; 127: 545–52.

Bambrook PN Eisman JA Champion GD Pocock NA . Sex hormone status and osteoporosis in post-menopausal women with rheumatoid arthritis. Arthritis Rheum 1988; 31: 973–8.

Parker LN Levin ER Liftrak ET . Evidence for adrenocortical adaptation to severe illness. J Clin Endocrinol Metab 1985; 60: 947–52.

Mulder JW Krifnen P Coutino RA Endert E Goudsmat J Lange JM . Dehydroepiandrosterone (DHEA) as a surrogate marker for monitoring zidovudine treatment (abstract). International Conference on AIDS: Amsterdam, Netherlands, July 19–24, 1992;127(2):B169.